Applications of complexation in the formulation of insoluble compounds

Water-Insoluble Drug Formulation, Second Edition

Volumn , Issue , 2008, Pages 133-159

  Tong, Wei Qin ^a   Wen, Hong ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123271651     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (117)

1. Aggarwal, S., Singh, P. N., and Mishra, B. 2002. Studies on solubility and hypoglycemic activity of gliclazide B-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie. 57: 191-193.
2. Ammar, H. O., Salama, H. A., Ghorab, M., and Mahmoud, A. A. 2006. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy. Int. J. Pharm. 320: 53-57.
3. Bary, A. R., Tucker, I. G., and Davies, N. M. 2001. An insight into how cyclodextrins increase the ocular bioavailability of poorly water-soluble compounds. Proceedings-28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer and Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001.
4. Basavaraj, S., Sihorkar, V., Kumar, T. R. S., Sundaramurthi, P., Srinivas, N. R., Venkatesh, P., Ramesh, M., and Singh, S. K. 2006. Bioavailability enhancement of poor water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-B-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component. Pharm. Dev. Tech. 11: 443-451.
5. Baszkin, A., Angelova, A., and Ringard-Lefebvre, C. 1999. Host-guest complexation of water soluble and water insoluble drugs by cyclodextrins. Book of Abstracts, 218th ACS National Meeting, New Orleans, August 22-26. COLL-011
6. Bender, M. L. and Komiyama, M. 1978. Cyclodextrin Chemistry, Berlin: Springer-Verlag.
7. Boje, K. M., Sak, M. and Fung, H. L. 1988. Complexation of nifedipine with substituted phenolic ligands. Pharm. Res. 5: 655-659.
8. Caira, M. R. and Dodds, D. R. 1999. Inclusion of nonopiate analgesic drugs in cyclodextrins. I. X-ray structure of a 1:1 beta-cyclodextrin-p-bromoacetanilide complex. J. Incl. Phenom. Macrocycl. Chem. 34: 19-29.
9. Cao, F., Guo, J., and Ping, Q. 2005. The physicochemical characteristics of freeze-dried scutellarin-cyclodextrin tetracomponent complexes. Drug Develop. Ind. Pharm. 31: 747-756.
10. Casu, B., Reggiani, M., Gallo, G. G., and Vigevanni, A. 1970. Conformation of amylose and its derived products. IV. Conformation of acetylated cyclodextrins and amylose. Carbohydr. Res. 12: 157-170.
11. Celebi, N. and Nagai, T. 1988. Improvement of dissolution characteristics of piromidic acid by dimethyl-B-cyclodextrin complexation. Drug Dev. Ind. Pharm. 14: 63-75.
12. Chen, A. X., Zito, S. W., and Nash, R. A. 1994. Solubility enhancement of nucleosides and structurally related compounds by complex formation. Pharm. Res. 11: 398-101.
13. Clarke, R. J., Coates, J. H., and Lincoln, S. F. 1988. Inclusion complexes of the cyclomalto-oligosaccharides. In Advances in Carbohydrate Chemistry and Biochemistry, edited by R. S. Tipson and D. Horton. San Diego: Academic Press, Inc.
14. Cohen, J. and Lach, J. L. 1963. Interaction of pharmaceuticals with Schardinger Dextrins I interaction with hydroxybenzoic acids and p-hydroxybenzoates. J. Pharm. Sci. 52: 132-136.
15. Connors, K. A. 1987. Binding Constants-The Measurement of Molecular Complex Stability. New York: John Wiley & Sons.
16. Connors, K. A. 1990. Complex formation. In Remington's Pharmaceutical Sciences, 18th ed., edited by A. R. Gebbaro: Mack Publishing Company.
17. Connors, K. A. 1997. The stability of cyclodextrin complexes in solution. Chem. Rev. 97: 1325-1357.
18. Cramer, F., Saenger, W., and Spatz, H. C. 1967. Inclusion compounds. XIX. The formation of inclusion compounds of A-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J. Am. Chem. Soc. 89: 14-20.
19. Cromwell, W. C., Bystrom, K., and Eftink, M. R. 1985. Cyclodextrin-adamantanecarboxylate inclusion complexes: studies of the variation in cavity size. J. Phys. Chem. 89: 326-332.
20. De Villiers, M. M., Liebenberg, W., Malan, S. F., and Gerber, J. J. 1999. The dissolution and complexing properties of ibuprofen and ketoprofen when mixed with N-methylglucamine. Drug Develop. Ind. Pharm. 25: 967-972.
21. Devarakonda, B., Hill, R. A., Liebenberg, W., Brits, M., and de Villiers, M. M. 2005. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int. J. Pharm. 304: 193-209.
22. Dilova, V., Zlatarova, V., Spirova, N., Filcheva, K., Pavlova, A., and Grigorova, P. 2004. Study of insolubility problems of dexamethasone and digoxin: cyclodextrin complexation. Boll. Chim. Farmac. 143: 20-23.
23. Donbrow, M., Touitou, E., and Ben Shalom, H. 1976. Stability of salicylamide-caffeine complex at different temperatures and its thermodynamic parameters. J. Pharm. Pharmac. 28: 766-769.
24. Duan, M. S., Zhao, N., Oessurardottir, I. B., Thorsteinsson, T., and Loftsson, T. 2005. Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: formation of aggregates and higher-order complexes. Int. J. Pharm. 297: 213-222.
25. Duchéne, D. and Wouessidjewe, D. 1990. The current state of B-cyclodextrin in pharmaceutics. Acta Pharm. Technol. 36: 1-6.
26. Eftink, M. R., Andy, M. L., Bystrom, K., Perlmutter, H. D., and Kristol, D. S. 1989. Cyclodextrin inclusion complexes: studies of the variation in the size of alicyclic guests. J. Am. Chem. Soc. 111: 6765-6772.
27. Emara, L. H., Badr, R. M., and Elbary, A. A. 2002. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Develop. Ind. Pharm. 28: 795-807.
28. Ficarra, R., Tommasini, S., Raneri, D., Calabro, M. L., Di Bella, M. R., Rustichelli, C., Gamberini, M. C., and Ficarra, P. 2002. Study of flavonoids/B-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, x-ray investigation. J. Pharm. Biomed. Anal. 29: 1005-1014.
29. Fini, A., Fernàndez-Hervàs, M. J., Holgado, M. A., Rodriguez, L., Cavallari, C., Passerini, N., and Caputo, O. 1997. Fractal analysis of B-cyclodextrin-indomethacin particles compacted by ultrasound. J. Pharm. Sci. 86:1303-1309.
30. Frijlink, H. W., Franssen, J. F., Eissens, A. C., Oosting, R., Lerk, C. F., and Meijer, D. K. F. 1991. The effect of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res. 8: 380-384.
31. Frömming, K. H. and Weyermann, I. 1973. Release of active substance after oral application of B-cyclodextrin inclusion compound to humans. Arzneim. Forsch. (Drug Res.), 23: 424-426.
32. Fugioka, K., Kurosaki, Y., Sato, S., Noguchi, T., and Yamahira, Y. 1983. Biopharmaceutical study of inclusion complexes. I. Pharmaceutical advantages of cyclodextrin complexes of bencyclane fumarate. Chem. Pharm. Bull., 31: 2416-2423.
33. Fukuda, N., Higuichi, N., Ohno, M., Kenmochi, H., Sekikawa, H., and Takada, M. 1986. Dissolution behavior of prednisone from solid dispersion systems with cyclodextrins and polyvinylpyrrolidone. Chem. Pharm. Bull. 34: 1366-1369.
34. Gibaud, S., Gaia, A., and Astier, A. 2002. Slow-release melarsoprol microparticles. Int. J. Pharm. 243: 161-166.
35. Gibaud, S., Ben Zirar, S., Mutzenhardt, P., Fries, I., and Astier, A. 2005. Melarsoprol-cyclodextrins inclusion complexes. Int. J. Pharm. 306: 107-121.
36. Glass, C. A. 1965. Proton magnetic resonance spectra of D-glucopyranose polymers. Can. J. Chem. 43: 2652-2659.
37. Green, A. R. and Guillory, J. K. 1989. Heptakis(2, 6-di-o-methyl)-B-cyclodextrin complexation with the antitumor agent chlorambucil. J. Pharm. Sci. 78: 427-431.
38. Guo, L. S. S., Fielding, R. M., Lasic, D. D., Hamilton, R. L., and Mufson, D. 1991. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75: 45-54.
39. Hansen, L. D., Lewis, E. A., and Ratough, D. J. 1985. In Analytical Solution Calorimetry, edited by J. K. Grime, New York: John Wiley & Sons, Inc.
40. Harata, K. 1989. Crystal structure of the inclusion complex of hexakis(2, 6-di-O-methyl)cyclomaltohexaose with 3-iodopropionic acid. Carbohydr. Res. 192:33-42.
41. Hersey, A., Robinson, B. H., and Kelly, H. C. 1986. Mechanisms of inclusion-compound formation for binding of organic dyes, ions and surfactants to A-cyclodextrin studied by kinetic methods based on competition experiments. J. Chem. Soc. Faraday Trans. 82: 1271-1287.
42. Higuchi, T. and Connors, K. A. 1965. In Advances in Analytical Chemistry and Instrumentation, Vol. 4. Edited by C. N. Reilly. New York: Interscience.
43. Higuchi, T. and Kristiansen, H. 1970. Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies. J. Pharm. Sci. 59: 1601-1608.
44. Hursthouse, M. B., Smith, C. Z., Thornton-Pett, M., and Utley, J. H. P. 1982. The x-ray crystal structure of an ethyl cinnamate-B-cyclodextrin guest-host complex. J. Chem. Soc. Chem. Commun., 15: 881-882.
45. Hussain, A. A. 1978. Novel 2-acetoxybenzoic acid-nicotinamide complexes. U.S. Patent 4120958.
46. Itoh, K., Tozuka, Y., Oguchi, T., and Yamamoto, K. 2003. Improvement of physicochemical properties of N-4472. Part III. VC/N-4472 complex formation and self-association in aqueous solution. Chem. Pharm. Bull. 51: 40-45.
47. Jambhekar, S., Casella, R., and Maher, T. 2004. The physicochemical characteristics and bioavailability of indomethacin from B-cyclodextrin, hydroxyethyl-B-cyclodextrin, and hydroxypropyl-B-cyclodextrin complexes. Int. J. Pharm. 270: 149-166.
48. Johnson, M. D., Hoesterey, B. L., and Anderson, B. D. 1994. Solubilization of a tripeptide HIV inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci. 83: 1142-1146.
49. Koehler, J. E. H., Saenger, W., and van Gunsteren, W. F. 1987. A molecular dynamics simulation of crystalline A-cyclodextrin hexahydrate. Eur. Biophys. J. 15: 197-210.
50. Koizumi, K. and Kidera, Y. 1977. Effect of A- and B-cyclodextrin on gastrointestinal absorption of barbituric acid derivatives. Yakugaku Zasshi, 97: 705-711.
51. Kreilgård, B., Higuchi, T., and Repta, A. J. 1975. Complexation of parenteral solutions: solubilization of cytoxic agent hexamethylmelamine by complexation with gentisic acid species. J. Pharm. Sci. 11: 1850-1855.
52. Kurozumi, M., Nambu, N., and Nagai, T. 1975. Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with A- and B-cyclodextrins in powdered form. Chem. Pharm. Bull. 23: 3062-3068.
53. Lach, J. L. and Pauli, W. A. 1966. Interaction of pharmaceuticals with Schardinger dextrins VI. Interactions of B-cyclodextrin, sodium deoxycholate, and deoxycholic acid with amines and pharmaceutical agents. J. Pharm. Sci. 55: 32-38.
54. Lahiani-Skiba, M., Barbot, C., Bounoure, F., Joudieh, S., and Skiba, M. 2006. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Drug Dev. Ind. Pharm. 32: 1043-1058.
55. Lantz, A. W., Rodriguez, M. A., Wetterer, S. M., and Armstrong, D.W. 2006. Estimation of association constants between oral malodor components and various native and derivatized cyclodextrins. Anal. Chim. Acta. 557: 184-190.
56. Lengyyel, M. T. and Szejtli, J. 1985. Menadione-gamma cyclodextrin inclusion complex. J. Incl. Phenom. 3: 1-8.
57. Lin, S. Y., Kao, Y. H., and Yong, J. C. 1988. Grinding effect on some pharmaceutical properties of drugs by adding B-cyclodextrin. Drug Develop. Ind. Pharm. 14: 99-118.
58. Loftsson, T., Leeves, N., Sigurjonsdottir, J. F., Sigurosson, H. H., and Masson, M. 2001. Sustained drug delivery system based on a cationic polymer and an anionic drug/cyclodextrin complex. Pharmazie. 56: 746-747.
59. Loftsson, T., Masson, M., and Sigurjonsdottir, J. F. 1999. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharm. Sci. 9: 237-242.
60. Loftsson, T. and Masson, M. 2001. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 225: 15-30.
61. Loftsson, T. and Masson, M. 2004. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J. Drug Delivery Sci. Technol. 14: 35-43.
62. Marletti, F. and Notelli, S. 1976. Charge-transfer complexes of p-hydroxyphenylbutazone. Il Farmaco. Ed. Sci. 31: 665-670.
63. Marttin, E., Verhoef, J. C., and Merkus, F. W. H. M. 1998. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6: 17-36.
64. Matsui, Y., Nishioka, T., and Fujita, T. 1985. Quantitative structure-reactivity analysis of the inclusion mechanism by cyclodextrins. Top. Curr. Chem. (Biomimetic Ioorg Chem.). 128: 61-89.
65. McGinity, J.W., Combs, A. B., and Martin, H. N. 1975. Improved method for microencapsulation of soluble pharmaceuticals. J. Pharm. Sci., 64: 889-890.
66. Mesens, L. J. and Putteman, P. 1991. Pharmaceutical applications of 2-hydroxypropyl-B-cyclodextrin. In New Trends in Cyclodextrins and Derivatives, Edited by D. Duchene. Paris:Editions de Santé.
67. Miro, A., Quaglia, F., Sorrentino, U., La Rotonda, M. I., D'Emmanuele Di Villa Bianca, R., and Sorrentino, R. 2004. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations. Eur. J. Pharm. Sci. 23: 57-64.
68. Mori, Y., Suzuki, A., Yoshino, K., and Kakihana, H. 1989. Complex formation of p-Boronophenylalanine with some monosaccharides. Pigment Cell Res. 2: 273-277.
69. Mukne, A. P. and Nagarsenker, M. S. 2004. Triamterene-B-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS Pharm. Sci. Tech. 51: Article 19.
70. Mura, P., Bettinetti, G. P., Cirri, M., Maestrelli, F., Sorrenti, M., and Catenacci, L. 2005. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-B-cyclodextrin ternary system. Eur. J. Pharm. Biopharm. 59: 99-106.
71. Nagase, Y., Hirata, M., Wada, K., Arima, H., Hirayama, F., Irie, T., Kikuchi, M., and Uekama, K. 2001. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether B-cyclodextrin. Int. J. Pharm. 229: 163-172.
72. Nakai, Y., Fukuoka, E., Nakajima, S., and Yamamoto, K. 1977. Effects of grinding on physical and chemical properties of crystalline medicinals with microcrystalline cellulose. I. Some physical properties of crystalline medicinals in ground mixtures. Chem. Pharm. Bull., 25: 3340-3346.
73. Nakai, Y., Nakajima, S., Yamamoto, K., Terada, K., and Konno, T. 1980. Effects of grinding on the physical and chemical properties of crystalline medicinals with microcrystalline cellulose V: comparison with tri-O-methyl-B-cyclodextrin ground mixtures. Chem. Pharm. Bull., 28: 1552-1558.
74. Nakanishi, K., Nadai, T., Masada, M., and Miyajima, K. 1992. Effect of cyclodextrins on biological membrane II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem. Pharm. Bull. 40: 1252-1256.
75. Nishijo, J., Ohno, K., Nishimura, K., Hukuda, M., Ishimaru, H., and Yonetani, I. 1982. Soluble complex formation of theophylline with aliphatic di- and monoamines in aqueous solution. Chem. Pharm. Bull. 30: 771-776.
76. Okimoto, K., Rajewski, R. A., Jona, J. A., and Stella, V. J. 1995. The interaction of charged and uncharged drugs with a neutral (HP-B-CD) and anionically charged (SBE-B-CD) B-cyclodextrin. Pharm. Res. 12: S205.
77. Okimoto, K., Rajewski, R. A., and Stella, V. J. 1999. Release of testosterone from an osmotic pump tablet utilizing (SBE)7m-B-cyclodextrin as both a solubilizing and an osmotic pump agent. J. Controlled Rel. 58: 29-38.
78. Palmieri, G. F., Galli-Angeli, D., Giovannucci, G., and Martelli, S. 1997. Inclusion of methoxybutropate in B- and hydroxypropyl B-cyclodextrins: comparison of preparation methods. Drug Develop. Ind. Pharm. 23: 27-37.
79. Patel, R. P., Sawant, K. K., Patel, M. M., and Patel, N. R. 2005. Enhancement of the dissolution properties of furosemide by inclusion complexation with B-cyclodextrin. Drug Delivery Technol. 5: 62-66.
80. Peeters, J., Neeskens, P., Adriaensen, J., and Brewster, M. 2002. Alfaxalone: effect of temperature on complexation with 2-hydroxypropyl-B-cyclodextrin. J. Incl. Phenom. Macrocyclic Chem. 44: 75-77.
81. Pitha, F. and Szente, L. 1984. Digitonin derivatives of low toxicity: potential solubilizers for lipophilic compounds. J. Pharm. Sci. 73: 240-243.
82. Pralhad, T. and Rajendrakumar, K. 2004. Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. J. Pharm. Biomed. Anal. 34: 333-339.
83. Puglisi, G., Santagati, N. A., Pignatello, R., Ventura, C., Bottino, F. A., Mangiafico, S., and Mazzone, G. 1990. Inclusion complexation of 4-biphenylacetic acid with B-cyclodextrin. Drug Develop. Ind. Pharm. 16: 395-413.
84. Rajendrakumar, K., Madhusudan, S., and Pralhad, T. 2005. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. Eur. J. Pharm. Biopharm. 60: 39-46.
85. Rajewski, R. A. and Stella, V. J. 1996. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery. J. Pharm. Sci. 85: 1142-1169.
86. Rao, V. S. R. and Foster, J. F. 1963. On the conformation of the D-glucopyranose ring in maltose and in higher polymers of D-glucose. J. Phys. Chem. 67: 951-952.
87. Repta, A. J. 1981. Alteration of apparent solubility through complexation. In Techniques of Solubilization of Drugs. Edited by S. H. Yalkowsky, New York: Marcel Dekker, Inc.
88. Repta, A. J. and Hincal, A. A. 1980. Complexation and solubilization of acronine with alkylgentisates. Int. J. Pharm. 5: 149-155.
89. Reuning, R. H. and Levy, G. 1968. Characterization of complex formation between small molecules by membrane permeation measurements. J. Pharm. Sci. 57: 1556-1561.
90. Rode, T., Frauen, M., Muller, B. W., Dusing, H. J., Schonrock, U., Mundt, C., and Wenck, H. 2003. Complex formation of sericoside with hydrophilic cyclodextrins: improvement of solubility and skin penetration in topical emulsion based formulations. Eur. J. Pharm. Biopharm. 55: 191-198.
91. Siimer, E., Kurvits, M., and Kostner, A. 1987. Thermochemical investigation of B-cyclodextrin complexes with benzoic acid and sodium benzoate. Thermochim. Acta 116: 249-256.
92. Simon, K., Stadler, A., and F. Hange, A. 1981. Investigation of cyclodextrin complexes by x-ray powder diffraction. Proc. Int. Symp. Cyclodextrins, 1st, Budapest, pp. 251-259.
93. Stella, V. J. and Rajewski, R. A. 1997. Cyclodextrins: their future in drug formulation and delivery, Pharm. Res. 14: 556-567.
94. Szejtli, J. 1982. Cyclodextrins and Their inclusion Complexes. Budapest:Akademiai Kiadó.
95. Szejtli, J. 1994. Medicinal applications of cyclodextrins. Med. Res. Rev. 14: 353-386.
96. Takayama, K., Nambu, N., and Nagai, T. 1977a. Interaction of sulfonamides with cyclic polyether 18-crown-6. Chem. Pharm. Bull. 25: 2608-2612.
97. Takayama, K., Nambu, N., and Nagai, T. 1977b. Interaction of n-methyl-2-pyrrolidone with aminobenzoic acids in solution and in solid state. Chem. Pharm. Bull. 25: 887-897.
98. Taneri, F., Guneri, T., Aigner, Z., Eroes, I., and Kata, M. 2003. Improvement of the physicochemical properties of clotrimazole by cyclodextrin complexation. J. Incl. Phenom. Macrocyclic Chem. 46: 1-13.
99. Thomason, M. A., Mwakibete, H., and Wyn-Jones, E. 1990. Ultrasonic and electrochemical studies on the interactions of the drug chlorocyclizine hydrochloride with A-cyclodextrin and surfactant micelles. J. Chem. Soc. Faraday Trans. 86: 1511-1515.
100. Thompson, D. O. 1997. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Therapeut. Drug Carrier Systems. 14: 1-104.
101. Tokumura, T., Ueda, H., Tsushima, Y., Kasai, M., Kayano, M., Amada, I., Machida, Y., and Nagai, T. 1984. Inclusion complex of cinnarizine with B-cyclodextrin in aqueous solution and in solid state. J. Incl. Phenom. 2: 511-521.
102. Tong, W.Q., Chin, T. F., and Guillory, J. K. 1991a. Microcalorimetric investigation of the complexation between 2-hydroxypropyl-B-cyclodextrin and amine drugs with the diphenylmethyl functionality. J. Pharm. Biomed. Anal. 9: 1139-1146.
103. Tong, W.Q., Lach, J. L., Chin, T. F., and Guillory, J. K. 1991b. Structural effects on the binding of amine drugs with the diphenylmethyl functionality to cyclodextrin I: a microcalorimetric study. Pharm. Res. 8: 951-957.
104. Tong, W. Q., Lach, J. L., Chin, T. F., and Guillory, J. K. 1991c. Structural effects on the binding of amine drugs with the diphenylmethyl functionality to cyclodextrin II: a molecular modeling study. Pharm. Res. 8: 1307-1312.
105. Truelove, J., Bawarshi-Nassar, R., Chen, N. R., and Hussain, A. 1984. Solubility enhancement of some developmental anti-cancer nucleoside analogs by complexation with nicotinamide. Int. J. Pharm. 19: 17-25.
106. Uekama, K. 1985. Pharmaceutical applications of methylated cyclodextrins. Pharm. Int. 5: 61-65.
107. Uekama, K., Ikeda, Y., Hirayama, F., Otagiri, M., and Shibata, M. 1980. Inclusion complexation of p-hydroxybenzoic acid esters with A- and B-cyclodextrins: dissolution behaviors and antimicrobial activities. Yakugaku Zasshi, 100: 994-1003.
108. Uekama, K., Fujinaga, T., Hirayama, F., Otagiri, M., Seo, H., and Tsuruoka, M. 1981. Proc. Int. Symp. Cyclodextrins, 1st, Budapest, p. 141.
109. Uekama, K., Fuginaga, T., Horayama, F., Otagiri, M., Yamasaki, M., Seo, H., Hashimoto, T., and Tsuruoka, M. 1983a. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J. Pharm. Sci. 72: 1338-1341.
110. Uekama, K., Narisawa, S., Hirayama, F., and Otagiri, M. 1983b. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int. J. Pharm. 16: 327-338.
111. Uekama, K., Otagiri, M., Uemura, Y., Fujinaga, T., Arimori, K., Matsuo, N., Tasaki, K., and Sugii, A. 1983. Improvement of oral bioavailability of prednisolone by B-cyclodextrin complexation in humans. J. Pharmacobio-Dyn. 6: 124-127.
112. Uekama, K. and Otagiri, M. 1987. Cyclodextrins in drug carrier systems. Crit. Rev. Therap. Drug Carrier Systems 3: 1-40.
113. Uekama, K., Hirayama, F., and Irie, T. 1994. Application of cyclodextrins. In Drug Absorption Enhancement: Drug Absorption Enhancement: Concepts, Possibilities and Limitationss Ed. A. G. Boer. Switzerland:Harwood Academic Publishers, 1994, pp. 411-456.
114. Vicens, J., Fujiwara, T., and Tomita, K.-I. 1988. X-ray structural studies of B-cyclodextrin inclusion complexes with racemic and S(-)methyl-p-tolylsulfoxides. J. Incl. Phenom. 6: 577-581.
115. Yang, G., Jain, N., and Yalkowsky, S.H. 2004. Combined effect of SLS and (SBE)7M-B-CD on the solubilization of NSC-639829. Int. J. Pharm. 269: 141-148.
116. Yang, W. and De Villiers, M. M. 2004. Aqueous solubilization of furosemide by supramolecular complexation with 4-sulphonic calix[n]arenes. J. Pharm. Pharmacol. 56: 703-708.
117. Yang, W. and De Villiers, M. M. 2005. Effect of 4-sulfonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poor water soluble anthelmintic. AAPS J. 7: E241-E248.